Koers Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE
Aandelen
US74365A1016
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 52,7 mln. 19,41 mld. 48,63 mln. | Omzet 2025 * | 101 mln. 37,34 mld. 93,57 mln. | Marktkapitalisatie | 76,98 mln. 28,35 mld. 71,04 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 8 mln. 2,95 mld. 7,38 mln. | Nettowinst (verlies) 2025 * | 54 mln. 19,89 mld. 49,83 mln. | EV/omzet 2024 * | 1,46 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,76 x |
K/w-verhouding 2024 * |
8,75
x | K/w-verhouding 2025 * |
1,67
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,42% |
Recentste transcriptie over Protalix Biotherapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30-06-19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22-07-19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01-12-19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01-12-19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01-11-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,97% | 45,34 mld. | |
+41,98% | 40,42 mld. | |
-10,06% | 37,92 mld. | |
+31,15% | 31,75 mld. | |
-7,79% | 27,71 mld. | |
+13,32% | 26,52 mld. | |
+43,05% | 13,96 mld. | |
+31,28% | 12,44 mld. | |
-7,41% | 11,26 mld. |